Routine

HIV pre-exposure prophylaxis (PrEP)

PrEP · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

PrEP is antiretroviral medication taken by HIV-negative people at substantial risk to prevent acquisition. Oral tenofovir/emtricitabine is highly effective; long-acting injectable cabotegravir is an alternative. HIV must be excluded before and monitored during use.

Red flags

  • Symptoms of acute HIV at or near initiation
  • New seroconversion on PrEP (switch to full ART)
  • Rising creatinine or declining GFR
  • Hepatitis B flare after abrupt tenofovir cessation

Assessment

Differential diagnosis

  • Undiagnosed acute HIV (contraindicates PrEP alone)
  • Chronic hepatitis B (affects tenofovir choice/stopping)
  • Renal impairment limiting tenofovir disoproxil
  • Established HIV requiring full ART
  • Other STI needing treatment

Investigations

  • Fourth-generation HIV antigen/antibody test (and viral load if acute suspected)
  • Renal function and estimated GFR
  • Hepatitis B surface antigen and immunity status
  • STI screen (gonorrhoea, chlamydia, syphilis)
  • Pregnancy test where relevant
  • Creatinine at baseline and during follow-up

Management

  • Confirm HIV-negative with recent test; exclude acute seroconversion symptoms
  • Assess ongoing HIV risk and eligibility
  • Check renal function and hepatitis B status
  • Counsel on daily (or event-based for eligible men) dosing and adherence
  • Prescribe tenofovir disoproxil/emtricitabine, or offer injectable cabotegravir if preferred/eligible
  • Advise condoms and screen/treat concurrent STIs
  • Vaccinate against hepatitis B, hepatitis A, HPV and mpox where indicated
  • Review at 1 month then every 3 months with repeat HIV test, STI screen and renal check
  • Plan PrEP-to-ART transition immediately if HIV diagnosed
  • Support safe stopping with tail cover; manage hepatitis B flare risk on discontinuation

Drugs & doses

Tenofovir disoproxil/emtricitabine 245/200 mg PO once daily
Event-based (2-1-1): two tablets 2-24 h before sex, one at 24 h, one at 48 h (eligible cisgender men)
Cabotegravir long-acting 600 mg IM at 0 and 1 month then every 2 months
Cabotegravir 30 mg PO once daily oral lead-in (optional before injectable)

Disposition

Sexual health / HIV prevention clinic; routine follow-up; urgent review if seroconversion.

Complications & pitfalls

  • Breakthrough HIV with integrase resistance (notably on injectable)
  • Renal toxicity with tenofovir disoproxil
  • Bone mineral density reduction
  • Hepatitis B reactivation on stopping
  • Ongoing STI acquisition

Exam pearls

  • Daily oral PrEP is near-fully protective with good adherence
  • Event-based dosing is validated only for anal sex in cisgender men
  • Injectable cabotegravir requires 3-monthly HIV RNA monitoring given risk of occult infection
  • Tenofovir alafenamide/emtricitabine is an option where renal/bone concerns exist (not for receptive vaginal exposure data-wise)
  • Always exclude acute HIV before starting

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.